<ins id="tvjhj"></ins>
<ins id="tvjhj"><noframes id="tvjhj"><ins id="tvjhj"></ins>
<cite id="tvjhj"><th id="tvjhj"></th></cite>
<del id="tvjhj"><noframes id="tvjhj"><del id="tvjhj"></del>
<cite id="tvjhj"><noframes id="tvjhj">
<cite id="tvjhj"><noframes id="tvjhj">
<ins id="tvjhj"><noframes id="tvjhj"><ins id="tvjhj"></ins>

A LONG-TERM FOCUS
ON INNOVATION

We welcome the opportunity to discuss:

BUSINESS
DEVELOPMENT
COLLABORATIONS

  • In-licensing and / or R&D collaborations
    • Creative collaborations in emerging fields
    • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
  • Strategic late-stage development and commercial partnerships with other leading biopharma companies
  • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

Introduce your assets or discuss
late-stage partnership

ACADEMIC &
RESEARCH
COLLABORATIONS

  • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

Learn more

  • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

Learn more

OUR BUSINESS DEVELOPMENT STRATEGY

Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

  • Novel platforms that enable next-generation therapeutics
  • Technologies for antibody discovery and development against new / challenging targets
  • New approaches that enhance activity of tumor-directed antibodies
  • Biomarker discovery and validation
  • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
  • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
  • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

SOME OF OUR CURRENT COLLABORATORS INCLUDE:


Bayer logo

Global ophthalmology
collaborations

Sanofi logo

Antibody and immunotherapy
collaborations

Icahn School of Medicine logo

Antibody discovery
agreement

Columbia University logo

Research collaboration on genetic
basis of familial disease

Teva logo

Global collaboration for
investigational pain therapeutic

Intellia Therapeutics logo

Gene-editing technology
collaboration

Adicet Bio logo

Engineered immune cell
therapeutics collaboration

Alnylam logo

RNA interference (RNAi)
therapeutics collaboration

久久日